⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685684 | 0.61 | — | — | |
| SCHEMBL406120 | 0.58 | — | — | |
| Ammonia Solution, Strong SCHEMBL5697195 | 0.55 | — | — | |
| SCHEMBL11854072 | 0.55 | — | — | |
| SCHEMBL15797702 | 0.55 | CA2 (0.36) | — | |
| SCHEMBL5869492 | 0.50 | — | — | |
| SCHEMBL2069806 | 0.50 | — | — | |
| SCHEMBL92678 | 0.50 | — | — | |
| SCHEMBL9470 | 0.50 | — | — | |
| SCHEMBL1355827 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952573-B2 | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-11932854-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| US-20230348904-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | BANK OF AMERICA, N.A. | 2023-11-02 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| US-20230144623-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | SIRNA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230030119-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS, INC | 2023-02-02 | — | — | US | disclosed |
| US-11530407-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529428-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | BANK OF AMERICA, N.A. | 2022-12-20 | — | — | US | disclosed |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006088490-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006088490-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
| EP-1539760-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018473-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2004-03-04 | — | — | WO | disclosed |
| US-20040039181-A1 | Process for preparing aromatic azo and hydrazo compounds, aromatic amides and aromatic amines | FLEXSYS AMERICA L.P. | 2004-02-26 | — | — | US | disclosed |
| US-5264438-A | Dopamine receptor agonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0436157-A1 | Quinazoline derivatives and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-10 | — | — | EP | disclosed |